title: Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure: results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol IN Chronic Heart Failure II (MAIN-CHF II) study.
abstract: Bisoprolol fumarate (bisoprolol) is a β-blocker widely used to treat chronic heart failure (CHF). However, few studies have compared its efficacy and safety with those of the widely used β-blocker carvedilol in Japanese patients with CHF. We designed a confirmatory trial of bisoprolol using carvedilol as a control drug; however, the trial was discontinued after an off-label use of bisoprolol was approved during the study. Bisoprolol and carvedilol were administered for 32 weeks in 31 and 28 patients, respectively. The mean maintenance doses of bisoprolol and carvedilol were 3.3 and 13.6 mg/day, respectively, and the mean durations of treatment were 188.2 and 172.9 days, respectively. Heart-rate changes were similar in both groups. The mean changes from baseline to Week 32 in left ventricular (LV) ejection fraction (EF) (bisoprolol vs carvedilol groups; 11.7 % ± 8.6 % vs 10.1 % ± 10.5 %), LV end-diastolic volume (-37.5 ± 48.7 vs -24.7 ± 29.4 ml), and LV end-systolic volume (-41.9 ± 43.0 vs -29.3 ± 25.9 ml) revealed a decrease in LV volume and an increase in LVEF in both groups. The cumulative event-free rate for a composite of cardiovascular death or admissions to hospital for worsening of CHF was 92.4 % and 94.7 % in the bisoprolol and carvedilol groups, respectively. Overall, 90.3 % and 85.7 % of patients were titrated up to the maintenance doses of bisoprolol and carvedilol, respectively. Bisoprolol, at half the dose used in other countries, is well tolerated and is as effective as carvedilol for treating Japanese patients with mild to moderate CHF.
authors.affiliation: Osaka Medical Center for Cancer and Cardiovascular Diseases, 1-3-3 Nakamichi, Higashinari-ku, Osaka, 537-8511, Japan, hori-ma@mc.pref.osaka.jp.
authors.forename: Masatsugu
authors.initials: M
authors.lastname: Hori
authors.forename: Ryozo
authors.initials: R
authors.lastname: Nagai
authors.forename: Tohru
authors.initials: T
authors.lastname: Izumi
authors.forename: Masunori
authors.initials: M
authors.lastname: Matsuzaki
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D000368:Aged; D017298:Bisoprolol / Q000008:administration & dosage* / Q000009:adverse effects; D002227:Carbazoles / Q000008:administration & dosage* / Q000009:adverse effects; D000077261:Carvedilol; D002908:Chronic Disease; D018572:Disease-Free Survival; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D057239:Early Termination of Clinical Trials; D005260:Female; D006333:Heart Failure / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged; D010343:Patient Admission; D011412:Propanolamines / Q000008:administration & dosage* / Q000009:adverse effects; D011446:Prospective Studies; D012720:Severity of Illness Index; D013318:Stroke Volume / Q000187:drug effects; D013997:Time Factors; D016896:Treatment Outcome; D016277:Ventricular Function, Left / Q000187:drug effects; D020257:Ventricular Remodeling / Q000187:drug effects
chemical_list: D000319:Adrenergic beta-Antagonists; D002227:Carbazoles; D011412:Propanolamines; D000077261:Carvedilol; D017298:Bisoprolol
references.citation: Ann Intern Med. 2009 Jun 2;150(11):784-94
references.pmid: 19487713
references.citation: Am Heart J. 2004 Feb;147(2):324-30
references.pmid: 14760332
references.citation: N Engl J Med. 1996 May 23;334(21):1349-55
references.pmid: 8614419
references.citation: Am J Cardiol. 2005 Sep 15;96(6):867-71
references.pmid: 16169379
references.citation: J Am Coll Cardiol. 2010 Jul 27;56(5):392-406
references.pmid: 20650361
references.citation: Eur J Heart Fail. 2011 Jun;13(6):670-80
references.pmid: 21429992
references.citation: Am J Cardiol. 2005 Sep 1;96(5):705-9
references.pmid: 16125500
references.citation: Eur Heart J. 2008 Oct;29(19):2388-442
references.pmid: 18799522
references.citation: Lancet. 1999 Jun 12;353(9169):2001-7
references.pmid: 10376614
references.citation: Circulation. 2009 Apr 14;119(14):e391-479
references.pmid: 19324966
references.citation: Lancet. 1999 Jan 2;353(9146):9-13
references.pmid: 10023943
references.citation: N Engl J Med. 2002 Jul 18;347(3):161-7
references.pmid: 12124404
references.citation: Eur Heart J. 2005 Nov;26(21):2259-68
references.pmid: 16040619
references.citation: J Card Fail. 2003 Oct;9(5):350-3
references.pmid: 14583894
references.citation: J Am Soc Echocardiogr. 1989 Sep-Oct;2(5):358-67
references.pmid: 2698218
references.citation: Circulation. 2001 Mar 13;103(10):1428-33
references.pmid: 11245648
references.citation: Circulation. 2002 May 21;105(20):2392-7
references.pmid: 12021226
references.citation: N Engl J Med. 2001 May 31;344(22):1651-8
references.pmid: 11386263
references.citation: Ann Intern Med. 2001 Apr 3;134(7):550-60
references.pmid: 11281737